Company intelligence / Profile preview

Xcel Peptides

Ownership: Private
Development stage: Other

Overview

Xcel Peptides markets synthetic peptides—such as BPC-157—for in-vitro and preclinical research use, emphasizing that all products are strictly not for human or animal use[3][7]. The company operates a GMP-certified, audited, and regulated facility for liquid aminos[6], but there is no public evidence of advancing any clinical trials or publishing clinical results.

Modalities: Peptides
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Xcel Peptides.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xcel Peptides.

Explore the full profile